10-Q: Lifecore Biomedical Reports Q1 2026 Results, Revenue Up 26%

Lifecore Biomedical, a CDMO and HA manufacturer, reported a 26% increase in total revenues to $31.1 million for the quarter ended September 30, 2025, alongside a reduced net loss.

Summary

• Total revenues increased 26% to $31.109 million for the three months ended September 30, 2025, compared to $24.705 million in the prior comparable period.
• HA manufacturing revenues surged 107% to $9.360 million, driven by increased demand from a customer due to supply chain initiatives.
• CDMO revenues increased 8% to $21.749 million, primarily from higher sales volumes.
• Gross profit rose 45% to $7.791 million, with the gross profit percentage improving to 25.0% from 21.8%.
• Operating loss significantly narrowed to $(3.067) million from $(11.584) million in the prior comparable period.
• Net loss decreased to $(9.991) million from $(16.230) million in the prior comparable period.
• Cash and cash equivalents at September 30, 2025, were $18.856 million, up from $8.265 million at May 25, 2025.
• The company completed its capacity expansion project, expected to more than double its overall aseptic capacity, leading to an estimated $1.6 million annual increase in depreciation.
• The fiscal year was changed from the last Sunday of May to December 31st, effective May 26, 2025.
• An agreement in principle was reached in November 2025 to settle a class action complaint, expected to be covered by the company's insurance policies with no material loss.
• The company paid $4.7 million in November 2025, fully satisfying outstanding registration delay fees related to preferred stockholders.
• Disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal control over financial reporting; a remediation plan is ongoing, including an ERP implementation targeted for Q1 2026.

Sentiment

Score: 6

Explanation: The company shows promising revenue growth and operational improvements, evidenced by the narrowed operating loss and increased gross profit. Resolution of the class action lawsuit and payment of preferred stock registration fees are positive steps in addressing legacy issues. However, the company continues to report a net loss, faces substantial debt obligations, and has a significant upcoming preferred stock redemption that it cannot fund internally, necessitating future capital raises. The ongoing material weaknesses in internal controls and other legal proceedings introduce considerable uncertainty and risk.

Positives

• Total revenues increased by 26% to $31.109 million, driven by strong performance in both HA manufacturing and CDMO segments.
• HA manufacturing revenues grew by 107% to $9.360 million, indicating robust customer demand.
• Gross profit increased by 45% to $7.791 million, with the gross profit percentage improving to 25.0% from 21.8%.
• Operating loss significantly narrowed to $(3.067) million from $(11.584) million, reflecting improved operational efficiency.
• Net loss decreased to $(9.991) million from $(16.230) million, showing progress in reducing overall losses.
• Cash and cash equivalents increased to $18.856 million, improving liquidity.
• Completion of a capacity expansion project is expected to more than double aseptic capacity, positioning the company for future growth.
• Selling, General, and Administrative (SG&A) expenses decreased by $5.9 million (40%), primarily due to reductions in recurring and non-recurring legacy-related costs.
• Workforce productivity improved by more than 20% over the past year.
• An agreement in principle to settle the class action complaint was reached, with the settlement expected to be covered by insurance, avoiding material loss to the company.
• The company fully paid $4.7 million in registration delay fees in November 2025, resolving a significant liability.

Negatives

• The company continues to report a net loss of $(9.991) million for the quarter.
• Interest expense, net, increased by $1.0 million (19%) to $(6.384) million, primarily due to accumulating interest on related-party term loans.
• A negative swing of $1.275 million occurred in the fair value of the debt derivative liability, moving from income to expense.
• The company experienced an income tax expense of $(0.333) million, compared to a benefit in the prior period, partly due to new Federal tax laws.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, due to material weaknesses in internal control over financial reporting.
• Total stockholders (deficit) equity moved from a positive $1.336 million at May 25, 2025, to a deficit of $(10.537) million at September 30, 2025.
• The company faces a significant aggregate liquidation preference of $47.466 million for its Redeemable Convertible Preferred Stock, which it cannot fund internally and will require external financing.
• Ongoing investor dispute (22NW Fund, L.P.) and Yucatan Litigation continue to create legal uncertainty and potential future costs.
• An SEC subpoena regarding financial statement restatement remains open, with unpredictable duration or outcome.

Risks

• The timing and amount of future expenses, revenue, cash flow, and capital requirements, and the timing and availability of additional financing.
• Ability to maintain or expand relationships with current customers, including the impact of changes in consumer demand for manufactured products.
• Ability to grow and diversify the business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals.
• Ability to comply with covenants under credit agreements and to pay required interest and principal payments when due.
• Ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances, or licensing arrangements.
• The impact of macroeconomic events or circumstances on operations and financial performance, including inflation, tariffs, interest rates, social unrest, and global instability.
• The performance of third-party suppliers.
• Pharmaceutical industry market forces that may impact customer success and continued demand for products.
• Ability to recruit or retain key scientific, technical, business development, and management personnel and executive officers.
• Ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice (cGMP).
• The outcome and cost of existing and any new litigation or regulatory proceedings.
• Material weaknesses in internal control over financial reporting, which led to ineffective disclosure controls and procedures as of September 30, 2025.
• The company's internally generated cash is not expected to be sufficient to fund all or any significant portion of the Series A Redeemable Convertible Preferred Stock liquidation preference of $47.5 million, due after June 29, 2026, necessitating consideration of financing alternatives.

Future Outlook

The company expects depreciation expense to increase by approximately $1.6 million per annum following the completion of its capacity expansion project. A new enterprise resource planning (ERP) system is targeted for launch in Q1 2026, which is anticipated to enhance inventory control, financial management, and cost reduction. Management expects current liquidity sources, including existing cash, cash generated from operations, and availability under the Revolving Credit Facility, to be sufficient to finance operational and capital requirements for at least the next twelve months. However, internally generated cash is not expected to be sufficient to fund the $47.5 million liquidation preference of the Series A Redeemable Convertible Preferred Stock, requiring the company to consider various financing alternatives.

Management Comments

• "Lifecore continues to make impactful improvements to operations, resulting in reduced operational expenses and improved productivity."
• "Through active management and targeted initiatives, the Company has improved workforce productivity by more than 20% over approximately the past year."
• "Lifecore plans to further maximize efficiencies and productivity via aggressive procurement and operational strategies."
• "The Company believes that a key catalyst in this effort will be the launch of its new enterprise resource planning (ERP) system, which is expected to go live in Q1 2026."
• "Lifecore expects this system to strengthen inventory control, support sharper financial management, and help reduce costs as the company grows."
• "To further advance the Companys efficiency objectives, Lifecore recently hired a seasoned industry executive in the role of head of business transformation."
• "The Company expects these sources [existing cash, cash from operations, Revolving Credit Facility] will be sufficient to finance its current operational and capital requirements for at least the next twelve months."

Industry Context

Lifecore Biomedical operates as a Contract Development and Manufacturing Organization (CDMO) and a Hyaluronic Acid (HA) manufacturer, positioning it within the pharmaceutical and medical device supply chain. The reported growth in HA manufacturing revenues suggests robust demand in related medical applications, such as ophthalmic and orthopedic uses. The company's strategic focus on operational efficiencies, including a new head of business transformation and an upcoming ERP system, aligns with broader industry trends emphasizing supply chain optimization, cost management, and enhanced data reliability in complex manufacturing environments. The completion of a significant capacity expansion project indicates a commitment to meeting growing market demand and strengthening its competitive position in aseptic manufacturing.

Management Changes

Corporate Governance

Legal Proceedings

• **Investor Dispute (22NW Fund, L.P.)**: Filed December 23, 2024, seeking money damages for alleged material misrepresentations, breaches of a stock purchase agreement, and registration delay fees, as well as specific performance to remove a conversion cap. The company filed a motion to dismiss most claims. A court hearing was held in early November 2025. The company intends to vigorously defend itself. The registration delay fees of $4.7 million were paid in full in November 2025, and the conversion cap was removed by stockholder approval in April 2025.
• **Class Action Complaint**: Filed July 29, 2024, alleging false and misleading statements regarding financial results and internal controls. An amended complaint was filed January 24, 2025. The company filed a motion to dismiss on March 25, 2025. An agreement in principle to settle the matter was reached in November 2025, expected to be covered by the company's insurance policies with no material loss incurred by the company.
• **SEC Subpoena**: Issued February 16, 2024, by the Chicago Regional Office of the SEC, seeking documents and information concerning the financial statement restatement. The company has cooperated, but the duration or outcome of this matter cannot be predicted.
• **Yucatan Litigation**: Lawsuit filed September 2, 2020, by a former owner seeking over $10 million. The company filed a cross-complaint seeking no less than $80 million. The first trial concluded October 18, 2024, resulting in a net award of $1.177 million in the company's favor. Both the company and the plaintiff filed appeals. A second trial for other defendants has been stayed. A new, duplicative complaint seeking over $15 million was filed by the plaintiff on June 30, 2025, which the company will oppose.

Related Party Transactions

• **Alcon Research, LLC**: Alcon is one of the company's largest customers, comprising 38% of revenues for the three months ended September 30, 2025. Alcon is also the lender for the Term Loan Credit Facility, with $179.562 million in principal outstanding as of September 30, 2025, bearing a 10% fixed interest rate (payable-in-kind until May 2026). Alcon is also involved in an equipment sale and leaseback transaction with the company, creating a $7.730 million leaseback liability. Alcon provided cash advances totaling $307 thousand for Alcon-owned equipment and a significant individual prepayment of $5.5 million in May 2024, accounted for as a contract liability.

Stakeholder Impact

• **Shareholders**: Potential for future dilution from capital raises to address preferred stock redemption. Resolution of the class action and registration fees reduces some legal uncertainty. Ongoing litigation and internal control weaknesses remain a concern.
• **Preferred Stockholders**: Received $4.7 million in registration delay fees. Have the right to redeem their stock after June 29, 2026, for a $47.5 million liquidation preference, which the company cannot fund internally, indicating a need for future financing.
• **Employees**: Improved workforce productivity by over 20%. A new head of business transformation has been hired to drive efficiency. Stock-based compensation plans are in place.
• **Customers**: Increased demand from a significant customer drove HA manufacturing revenue. Alcon remains a major customer with guaranteed purchasing commitments through 2031. The completed capacity expansion aims to improve manufacturing capabilities and service.
• **Creditors (Alcon, BMO)**: The company is in compliance with all financial covenants under the Term Loan Credit Facility and Revolving Credit Facility. Amendments to credit agreements provide flexibility. Alcon holds significant influence as both a major customer and creditor.

Next Steps

• Launch a new enterprise resource planning (ERP) system in Q1 2026 to improve financial management and cost control.
• Continue to execute the remediation plan to address identified material weaknesses in internal control over financial reporting.
• Test and monitor the design and operating effectiveness of internal controls following the ERP implementation.
• Evaluate and enhance the design of controls to ensure the completeness and accuracy of information used in financial reporting.
• Vigorously defend against the 22NW Fund, L.P. investor dispute if the settlement is not approved.
• Oppose and seek to dismiss the new duplicative complaint filed in the Yucatan Litigation.
• Consider various financing alternatives to fund the Series A Redeemable Convertible Preferred Stock liquidation preference.
• Deliver audited financial statements for the accounting period ending December 31, 2025, covering May 26, 2025, to December 31, 2025.
• Deliver preliminary draft of unaudited non-GAAP financial reports within 14 business days after the end of the third month of each fiscal quarter.
• Deliver an annual enterprise valuation report by February 15th of each fiscal year, with a preliminary draft by January 31st.

Key Dates

Recommendation

The company demonstrates promising revenue growth and operational improvements, evidenced by a narrowed operating loss and increased gross profit. The resolution of the class action lawsuit and the payment of preferred stock registration fees are positive steps in addressing legacy issues. However, the company continues to report a net loss, faces substantial debt obligations, and has a significant upcoming preferred stock redemption that it cannot fund internally, necessitating future capital raises. The ongoing material weaknesses in internal controls and other legal proceedings introduce considerable uncertainty and risk. A 'Hold' recommendation reflects the balance between the operational positives and the significant financial and governance challenges that need to be resolved before a more bullish stance can be taken.

Keywords

CDMO, HA manufacturing, sterile injectables, pharmaceutical, contract development, manufacturing, financial results, 10-Q, Lifecore Biomedical, LFCR, corporate governance, risk management, SEC filing, financial reporting, debt, litigation, internal controls, hyaluronic acid